palmitoylethanolamide.com.au
HomeResearchTeresa 2016

Ultramicronized palmitoylethanolamide reduces viscerovisceral hyperalgesia in a rat model of endometriosis plus ureteral calculosis: role of mast cells

Teresa Iuvone, Giannapia Affaitati, Daniele De Filippis, Mariangela Lopopolo, Gianluca Grassia, Domenico Lapenna, Luana Negro, Raffaele Costantini, Massimo Vaia, Francesco Cipollone, Armando Ialenti, Maria Adele Giamberardino. Pain. 2016;157(1):80-91.

Laboratory studyOther animals

Design
Laboratory study
Subjects
Female Sprague-Dawley rats with surgically induced endometriosis, later given ureteral stones
Dose used in the study
Ultramicronised PEA, 10 mg/kg by mouth daily, or placebo
Duration
25 days of treatment
What was measured
Ureteral and uterine pain behaviour, stone expulsion, cyst size, mast cell activity, blood vessel count, chymase, nerve growth factor and VEGF in cysts, and nerve growth factor in dorsal root ganglia.

What the authors reported

PEA-treated rats had fewer, shorter and less complex ureteral pain episodes, shorter uterine pain, smaller cysts, and a higher rate of stone expulsion than placebo-treated rats. Mast cell numbers, blood vessel counts, chymase, nerve growth factor and VEGF in cysts were all lower with PEA, as was nerve growth factor in dorsal root ganglia.

Limits of this study

A rat model combining surgical endometriosis and ureteral stones; it cannot show effect in people with endometriosis. A published comment and reply have questioned aspects of this paper (PMID 26871399 and 26871400). Funding and conflicts not stated in the abstract.

Source

PubMed 25974242 · doi:10.1097/j.pain.0000000000000220

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.